Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2019) 7 P147 | DOI: 10.1530/boneabs.7.P147

ICCBH2019 Poster Presentations (1) (226 abstracts)

Changes in DXA Z-scores during bisphosphonate (BP) therapy in patients with osteogenesis imperfecta (OI) at a tertiary care hospital in South Africa

Akhona Siralarala , John Morley Pettifor & Kebashni Thandrayen

C.H Baragwanath Academic Hospital, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand., Johannesburg, South Africa.

Objectives: The aim of this study was to evaluate and assess the change in bone mineral density in OI children treated with BPs at Chris Hani Baragwanath Academic hospital (CHBAH), South Africa.

Methods: Medical files of 104 OI patients who were seen at Metabolic Bone clinic from 01 January 2006 till 31 December 2015 were reviewed. DXA measurements were available on 33 patients that received bisphosphonates from baseline and during therapy at three time points (9–18 months, 18–30 months and >30 months). Three methods using white male and female reference values for calculating bone mineral content (BMC) and bone mineral density (BMD) Z-scores on whole body less head (WBLH) and lumbar spine (LS) were applied and analysed as follows: 1) Calculated Z-scores using the Zemel Default (1,2) and 2) Height adjusted Z-scores for >5 year old children only (1) and 3) DXA machine calculated Z-scores.

Results: WBLH BMC and BMD Z-scores and LS BMC and BMD Z-scores showed significant increases over 30 months of treatment (P<0.01). The mean BMC and BMD Z-scores (WBLH and LS) at baseline were < −2 confirming low bone mass. Mean calculated Z-scores after 30 months had reached a Z-score > −2; mean height adjusted Z-scores reached a Z-score > −2 from 9–18 months onwards and mean DXA machine calculated Z-scores reached a mean Z-score > −2 after 18 months. At baseline, 83% of patients had a LS BMD height adjusted Z-score < −2 and after 30 months of BPs treatment, none of the patients had a LS BMD height adjusted Z-score < −2 (P<0.001).The mean fracture rate at baseline prior to BP therapy was 16.44 (95% CI: −1.98 to 34.85) and significantly decreased to 0.62 (0.27–0.97) at 9–18 months and to 1.1 (0.49–1.65) at >30 months (P<0.001) during BP therapy.

Conclusion: Bisphosphonate therapy significantly increased height adjusted LS BMD Z-scores to >−2 and decreased the number of fractures after 9–18 months of treatment in South African OI patients thus supporting the use of BPs in OI patients to minimise hospitalisation and treatment costs related to fractures.

References: 1.

2. J Bone Miner Res. 2013 January; 28(1):206–212

Disclosure: The authors declared no competing interests.

Volume 7

9th International Conference on Children's Bone Health


Browse other volumes

Article tools

My recent searches

No recent searches.